Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by David Nemirovsky
Lesion-level PET/CT analysis to identify predictors of progression after BCMA CAR T-cell therapy in multiple myeloma
Dear Editor, B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy produces high response rates and durable remissions in relapsed/refractory multiple myeloma (RRMM), yet most patients ultimately relapse [1, 2]. Serologic markers and marrow-based minimal residual disease are used to monitor for progression and assess systemic disease burden, but they do not capture the anatomic distribution or lesion-level heterogeneity of resistant disease [3, 4].
Impact of granulocyte colony-stimulating factors on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma
|
Abstract Bispecific antibody (BsAb) treatment in multiple myeloma can be associated with adverse events including cytokine release syndrome (CRS), cytopenias, and infections. While granulocyte colony-stimulating factors (G-CSF) can be used to treat neutropenia, little is known about their safety during the BsAb initiation period and whether G-CSF can increase the risk of CRS.
By Alice Wang, David Nemirovsky, Andriy Derkach, Carlyn Tan, Issam S. Hamadeh, Ross Firestone, Eric Jurgens, Kevin Miller, Dhwani Patel, Neha Korde, Alexander M. Lesokhin, Sham Mailankody, Hani Hassoun, Hamza Hashmi, Sridevi Rajeeve, Urvi A. Shah, Kylee H. Maclachlan, Gunjan L. Shah, Michael Scordo, Heather Landau, Sergio A. Giralt, Saad Usmani, Malin Hultcrantz, Tala Shekarkhand
|
Nature
Verified
Robust CD4 + CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma
|
Editor’s summary Abstract Supplementary Materials REFERENCES AND NOTES Information & Authors Metrics & Citations Check Access References Figures Tables Media Share Editor’s summary The underlying cause of nonimmune effector cell–associated neurotoxicity syndrome neurotoxicities (NINTs) in patients treated with the chimeric antigen receptor T cell (CAR T cell) therapy ciltacabtagene autoleucel is poorly understood. Here, Jurgens et al.
By Lorena F Fernandes, Andre Matos, Eric Jurgens, Sneha Mitra, Kevin Herrera, David Nemirovsky, Andriy Derkach, Kinga Hosszu, Devin McAvoy, Ross Firestone, Sridevi Rajeeve, Alexander M. Lesokhin, Neha Korde, Carlyn Tan, Hamza Hashmi, Hani Hassoun, Kylee H. Maclachlan, Urvi A. Shah, Malin Hultcrantz, Maximilian Merz, Francesco Maura, Sergio A. Giralt, Gunjan L. Shah, Heather Landau, Brenden Bready
|
Science Magazine
Verified
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma
|
Abstract While CAR T has shown superior efficacy in earlier line of therapy [1, 2] for functionally high-risk multiple myeloma (FHRMM), outcomes with its use in later lines (3+) for FHR disease remain unknown. We describe a single-center experience of FHRMM patients (pts), defined as those with progression of disease (POD) < 24 months of frontline therapy, receiving CAR T-cell therapy.
By Hamza Hashmi, Tara M. Sebastian, Sridevi Rajeeve, Ross Firestone, Eric Jurgens, Kevin Miller, Francesco Maura, Alexander M. Lesokhin, Carlyn Tan, Gunjan L. Shah, Neha Korde, Heather Landau, Michael Scordo, Hani Hassoun, Kylee H. Maclachlan, Urvi A. Shah, Malin Hultcrantz, Andriy Derkach, David Nemirovsky, Sergio A. Giralt, Sham Mailankody, Saad Usmani, Tasmin Farzana, Maximillian Merz
|
Nature
Verified
Real-world experience of belumosudil and belumosudil/ruxolitinib combination in steroid-refractory chronic graft-versus-host disease - Bone Marrow Transplantation
Abstract Belumosudil is approved after failure of ≥2 lines of therapy in chronic graft-versus-host disease cGVHD. However, real-world data is limited. We conducted a retrospective analysis of 67 patients with steroid-refractory or dependent (SR/SD) cGVHD. At baseline, most patients had advanced multi-organ cGVHD. The 6- and 12-month overall response rate (ORR) was 61%. However, a subset of patients achieved deeper responses with ongoing therapy at 12 months.
Venetoclax in Combination With Pediatric‐Inspired Chemotherapy in Adults With Newly Diagnosed Acute Lymphoblastic Leukemia: Results of a Phase I Trial
To the Editor, While the outcomes of acute lymphoblastic leukemia (ALL) treatment in young children are excellent with > 90% long-term event-free survival (EFS) [1], outcomes among adults have continued to lag behind. Even with the utilization of pediatric-inspired chemotherapy (PIC) regimens, there remains a significant unmet need for 25%–40% of adult ALL patients who are not cured with upfront chemotherapy [2, 3].
"Interaction between Myelodysplasia-Related Gene Mutations and Ontogeny" by Joseph G W McCarter, David Nemirovsky et al.
Abstract Accurate classification and risk stratification are critical for clinical decision making in patients with acute myeloid leukemia (AML).
Chemotherapy response in low‐grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies
ORIGINAL ARTICLE The first two authors contributed equally to this article. Abstract Background Data on platinum sensitivity of low-grade serous ovarian carcinoma (LGSOC) in the upfront setting is lacking, and there is limited and contradictory information on chemotherapy responses in recurrent disease. Methods Patients with LGSOC seen at a comprehensive cancer center from January 1, 1998 to September 30, 2021 were identified from institutional databases.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with David
Contact David, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack